Medication-Induced Leukopenia
Chemotherapy Agents
- Chemotherapy drugs frequently cause leukopenia due to their direct myelosuppressive effects on bone marrow, with different regimens showing varying rates of leukopenia 1, 2, 3
- The following chemotherapy regimens have been associated with leukopenia:
- Dose-intensity and scheduling of chemotherapy significantly impact the risk of leukopenia 5, 6
Immunosuppressants and Antibiotics
- Immunosuppressive medications used in transplant recipients frequently cause leukopenia 7
- Trimethoprim-sulfamethoxazole and Ganciclovir have been associated with leukopenia 7
Risk Factors and Monitoring
- Advanced age is a risk factor for medication-induced leukopenia 6
- Renal or hepatic dysfunction is a risk factor for medication-induced leukopenia 7
- Baseline complete blood count before starting high-risk medications is recommended 5
- Consider G-CSF (granulocyte colony-stimulating factor) for high-risk patients with febrile neutropenia 5
Management Considerations
- For chemotherapy-induced leukopenia, colony-stimulating factors (CSFs) should be considered for patients with fever and neutropenia who are at high risk for infection-related complications 5, 6
Hematologic Toxicities of Vorinostat
Introduction to Vorinostat-Induced Hematologic Toxicities
- Vorinostat can directly cause both leukopenia and anemia, as hematologic toxicities are well-documented adverse effects of this HDAC inhibitor, according to the American Academy of Dermatology 8
Clinical Presentation of Hematologic Toxicities
The American Academy of Dermatology notes that hematologic toxicities, including leukopenia and anemia, are common adverse effects of vorinostat, with leukopenia occurring in 20-42% of patients across multiple clinical trials, although the exact percentage is not specified in this context 8
Management and Monitoring of Hematologic Toxicities
The American Academy of Dermatology recommends monitoring CBC weekly during initial therapy, then every 2-4 weeks once stable, to manage and monitor hematologic toxicities associated with vorinostat 8